133 related articles for article (PubMed ID: 20395019)
1. Structural determinants of resveratrol for cell proliferation inhibition potency: experimental and docking studies of new analogs.
Mazué F; Colin D; Gobbo J; Wegner M; Rescifina A; Spatafora C; Fasseur D; Delmas D; Meunier P; Tringali C; Latruffe N
Eur J Med Chem; 2010 Jul; 45(7):2972-80. PubMed ID: 20395019
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol analog (Z)-3,5,4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization.
Schneider Y; Chabert P; Stutzmann J; Coelho D; Fougerousse A; Gossé F; Launay JF; Brouillard R; Raul F
Int J Cancer; 2003 Nov; 107(2):189-96. PubMed ID: 12949793
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents.
Ruan BF; Lu X; Li TT; Tang JF; Wei Y; Wang XL; Zheng SL; Yao RS; Zhu HL
Bioorg Med Chem; 2012 Jan; 20(2):1113-21. PubMed ID: 22189271
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cancer derived cell lines proliferation by synthesized hydroxylated stilbenes and new ferrocenyl-stilbene analogs. Comparison with resveratrol.
Chalal M; Delmas D; Meunier P; Latruffe N; Vervandier-Fasseur D
Molecules; 2014 Jun; 19(6):7850-68. PubMed ID: 24962390
[TBL] [Abstract][Full Text] [Related]
5. Anti-mitotic properties of resveratrol analog (Z)-3,5,4'-trimethoxystilbene.
Chabert P; Fougerousse A; Brouillard R
Biofactors; 2006; 27(1-4):37-46. PubMed ID: 17012762
[TBL] [Abstract][Full Text] [Related]
6. Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents.
Penthala NR; Thakkar S; Crooks PA
Bioorg Med Chem Lett; 2015 Jul; 25(14):2763-7. PubMed ID: 26022840
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents.
Ruan BF; Lu X; Tang JF; Wei Y; Wang XL; Zhang YB; Wang LS; Zhu HL
Bioorg Med Chem; 2011 Apr; 19(8):2688-95. PubMed ID: 21440448
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells.
Delmas D; Passilly-Degrace P; Jannin B; Cherkaoui Malki M; Latruffe N
Int J Mol Med; 2002 Aug; 10(2):193-9. PubMed ID: 12119558
[TBL] [Abstract][Full Text] [Related]
9. Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action.
Scherzberg MC; Kiehl A; Zivkovic A; Stark H; Stein J; Fürst R; Steinhilber D; Ulrich-Rückert S
Toxicol Appl Pharmacol; 2015 Aug; 287(1):67-76. PubMed ID: 26044878
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells.
Marel AK; Lizard G; Izard JC; Latruffe N; Delmas D
Mol Nutr Food Res; 2008 May; 52(5):538-48. PubMed ID: 18384089
[TBL] [Abstract][Full Text] [Related]
11. 4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.
Liu T; Cui R; Chen J; Zhang J; He Q; Yang B; Hu Y
Arch Pharm (Weinheim); 2011 May; 344(5):279-86. PubMed ID: 21290430
[TBL] [Abstract][Full Text] [Related]
12. Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism.
Simoni D; Roberti M; Invidiata FP; Aiello E; Aiello S; Marchetti P; Baruchello R; Eleopra M; Di Cristina A; Grimaudo S; Gebbia N; Crosta L; Dieli F; Tolomeo M
Bioorg Med Chem Lett; 2006 Jun; 16(12):3245-8. PubMed ID: 16580204
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.
Pettit GR; Rhodes MR; Herald DL; Hamel E; Schmidt JM; Pettit RK
J Med Chem; 2005 Jun; 48(12):4087-99. PubMed ID: 15943482
[TBL] [Abstract][Full Text] [Related]
14. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
Simoni D; Romagnoli R; Baruchello R; Rondanin R; Grisolia G; Eleopra M; Rizzi M; Tolomeo M; Giannini G; Alloatti D; Castorina M; Marcellini M; Pisano C
J Med Chem; 2008 Oct; 51(19):6211-5. PubMed ID: 18783207
[TBL] [Abstract][Full Text] [Related]
15. Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
Carr M; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
Eur J Med Chem; 2010 Dec; 45(12):5752-66. PubMed ID: 20933304
[TBL] [Abstract][Full Text] [Related]
16. The resveratrol analogue 4,4'-dihydroxy-trans-stilbene inhibits cell proliferation with higher efficiency but different mechanism from resveratrol.
Savio M; Coppa T; Bianchi L; Vannini V; Maga G; Forti L; Cazzalini O; Lazzè MC; Perucca P; Prosperi E; Stivala LA
Int J Biochem Cell Biol; 2009 Dec; 41(12):2493-502. PubMed ID: 19679195
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of vinylogous combretastatin A-4 derivatives.
Kaffy J; Pontikis R; Florent JC; Monneret C
Org Biomol Chem; 2005 Jul; 3(14):2657-60. PubMed ID: 15999202
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of resveratrol-based nitrovinylstilbenes as antimitotic agents.
Reddy MA; Jain N; Yada D; Kishore C; Vangala JR; P Surendra R; Addlagatta A; Kalivendi SV; Sreedhar B
J Med Chem; 2011 Oct; 54(19):6751-60. PubMed ID: 21851083
[TBL] [Abstract][Full Text] [Related]
19. Finding more active antioxidants and cancer chemoprevention agents by elongating the conjugated links of resveratrol.
Tang JJ; Fan GJ; Dai F; Ding DJ; Wang Q; Lu DL; Li RR; Li XZ; Hu LM; Jin XL; Zhou B
Free Radic Biol Med; 2011 May; 50(10):1447-57. PubMed ID: 21376113
[TBL] [Abstract][Full Text] [Related]
20. Chemical modifications of resveratrol for improved protein kinase C alpha activity.
Das J; Pany S; Majhi A
Bioorg Med Chem; 2011 Sep; 19(18):5321-33. PubMed ID: 21880495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
